Literature DB >> 1720779

Integrin alpha IIb beta 3 (platelet GPIIb-IIIa) recognizes multiple sites in fibronectin.

R D Bowditch1, C E Halloran, S Aota, M Obara, E F Plow, K M Yamada, M H Ginsberg.   

Abstract

The binding of fibronectin (Fn) to several integrins involves the Arg-Gly-Asp (RGD) tripeptide sequence. However, linear synthetic RGD peptides do not completely mimic the cell attachment activity of intact Fn or certain large Fn fragments. This suggests that the integrin-Fn interaction involves a more extended surface of Fn than that provided by the RGD sequence. To test this possibility, three novel monoclonal anti-Fn antibodies that inhibit its binding to a purified integrin, alpha IIb beta 3, were developed. The epitopes of these three antibodies mapped to a region at least 55 residues amino-terminal of the RGD sequence. Further, recombinant fragments of Fn containing these epitopes and lacking the RGD site also inhibited the binding of Fn to purified alpha IIb beta 3. These fragments, which spanned Fn residues 1359-1436, bound to alpha IIb beta 3 in a divalent cation-dependent manner. In addition, this region of Fn bound specifically to alpha IIb beta 3 on thrombin-stimulated but not resting platelets. These results demonstrate the presence of additional sequences in Fn that interact with integrin alpha IIb beta 3 and suggest that multiple sites in Fn are involved in its recognition by this integrin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720779

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Fibronectin peptides in cell migration and wound repair.

Authors:  K M Yamada
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 2.  Functional peptide sequences derived from extracellular matrix glycoproteins and their receptors: strategies to improve neuronal regeneration.

Authors:  Sally Meiners; Mary Lynn T Mercado
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

3.  Structural requirements for biological activity of the ninth and tenth FIII domains of human fibronectin.

Authors:  R P Grant; C Spitzfaden; H Altroff; I D Campbell; H J Mardon
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

4.  Ail protein binds ninth type III fibronectin repeat (9FNIII) within central 120-kDa region of fibronectin to facilitate cell binding by Yersinia pestis.

Authors:  Tiffany M Tsang; Douglas S Annis; Malte Kronshage; Jesse T Fenno; Lisa D Usselman; Deane F Mosher; Eric S Krukonis
Journal:  J Biol Chem       Date:  2012-03-23       Impact factor: 5.157

5.  Titanium alloy surface oxide modulates the conformation of adsorbed fibronectin to enhance its binding to α(5) β(1) integrins in osteoblasts.

Authors:  Bruce E Rapuano; Jani J E Lee; Daniel E MacDonald
Journal:  Eur J Oral Sci       Date:  2012-05-08       Impact factor: 2.612

6.  The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.

Authors:  S Rahman; X Lu; V V Kakkar; K S Authi
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

7.  Integrin alpha 8 beta 1 promotes attachment, cell spreading, and neurite outgrowth on fibronectin.

Authors:  U Müller; B Bossy; K Venstrom; L F Reichardt
Journal:  Mol Biol Cell       Date:  1995-04       Impact factor: 4.138

8.  Delineation of Borrelia burgdorferi p66 sequences required for integrin alpha(IIb)beta(3) recognition.

Authors:  G Defoe; J Coburn
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  Carbodiimide conjugation of fibronectin on collagen basal lamina analogs enhances cellular binding domains and epithelialization.

Authors:  Katie A Bush; George D Pins
Journal:  Tissue Eng Part A       Date:  2010-03       Impact factor: 3.845

10.  In vitro selection of fibronectin gain-of-function mutations.

Authors:  Patricia H Tani; Joseph C Loftus; Ron D Bowditch
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.